Stock Financial Ratios, Dividends, Split History

GEN / Genesis Healthcare, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)184.14
Enterprise Value ($M)642.57
Book Value ($M)-1,159.19
Book Value / Share-11.71
Price / Book-0.16
NCAV ($M)-1,590.32
NCAV / Share-16.06
Price / NCAV-0.09
Share Statistics
Common Shares Outstanding3 61,477,303
Weighted Average Number Of Shares Outstanding Basic 94,217,000
Common Shares Outstanding2 744,396
Common Shares Outstanding 97,224,842
Weighted Average Number Of Diluted Shares Outstanding 94,217,000
Scoring Models
Piotroski F-Score2.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-47.88
Return on Assets (ROA)-0.17
Return on Equity (ROE)1.96
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ratio1.11
Income Statement (mra) ($M)
Health Care Organization Revenue5,373,740,000.00
Health Care Organization Patient Service Revenue0.00
Lease Facility Revenue0.00
Disposal Group Including Discontinued Operation Revenue0.00
Intersegment Revenue0.00
Revenues Including Revenue From Contract With Customer0.00
Net Income-959.20
Earnings Per Share Basic-6.15
Earnings Per Share Basic And Diluted0.00
Earnings Per Share Diluted-6.15
Cash Flow Statement (mra) ($M)
Cash From Operations120.45
Cash from Investing55.49
Cash from Financing55.49
Identifiers and Descriptors
Central Index Key (CIK)1351051

Split History

Stock splits are used by Genesis Healthcare, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

CYTX: Cytori Therapeutics Analysis and Research Report

4h - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CATB: Catabasis Pharmaceuticals Analysis and Research Report

2018-07-13 - Asif

Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...

WMT: Walmart Analysis and Research Report

2018-07-09 - Asif

Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...

Related News Stories

Sabra Health Care Disposes Genesis & Signature Facilities

2018-07-12 zacks
Recently, Sabra Health Care REIT (SBRA - Free Report) announced the selling of nine healthcare facilities leased to Genesis Healthcare (GEN - Free Report) on Jun 29, in a bid to dispose the properties leased to the latter. These healthcare facilities have been sold for $81.4 million. (1-0)

Acquisitions Aid Revenue Growth at Ensign Group (ENSG)

2018-07-11 zacks
The Ensign Group, Inc. (ENSG - Free Report) boasts a strong inorganic growth story, with more than 234 acquisitions made over 18 years. Its historical growth has been mainly driven by its expertise in acquiring real estate or leasing post-acute care operations and transforming those into market leaders. With each acquisition, the company had sharpened its expertise, both clinically and financially.

National Health Investors: Better Choice Than Omega Or Ventas?

2018-07-09 seekingalpha
Too much emphasis has been placed on future demand for senior housing, with less emphasis on the dynamics of supply and cost pressure on tenants.

Sabra Healthcare: Dealing With Challenges

2018-06-05 seekingalpha
The stock had moved to our second largest position thanks to our April puts being exercised. (2-0)

Apollo Investment's (AINV) CEO Jim Zelter on Q4 2018 Results - Earnings Call Transcript

2018-05-18 seekingalpha
Good morning and welcome to Apollo Investment Corporation’s Earnings Conference Call for the period ended March 31, 2018. At this time, all participants have been placed in a listen-only mode. The call will be opened for a question-and-answer session following the speakers’ prepared remarks. [Operator Instructions] (18-0)